MONTE ROSA THERAPEUTICS INC (GLUE)
Health Care · Protein degradation therapeutics / targeted protein degradation · NASDAQ
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its proprietary QuEEN discovery platform.
What MONTE ROSA THERAPEUTICS INC does
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing molecular glue degraders (MGDs), a class of small-molecule therapeutics designed to degrade disease-causing proteins. The company leverages its proprietary QuEEN discovery engine and proteomics capabilities to identify and target proteins previously considered undruggable or inadequately addressed by conventional approaches. Monte Rosa has a pipeline of internally developed MGD candidates targeting GSPT1 (MRT-2359), NEK7 (MRT-8102), CDK2/CCNE1, and has partnered VAV1-directed programs (MRT-6160) with Novartis and Roche.
Themes: Protein degradation / molecular glue degraders, Undruggable protein targets, Oncology, Drug discovery platform, Precision medicine
Fundamentals
- Price$14.30 as of 2026-08-21 close
- Market cap$1.2B as of 2026-08-21
- 1-year return+217.8% 2025-08-21 close $4.50 → 2026-08-21 close $14.30
- P/En/a negative earnings
- Net margin-560.9% as of 2026-08-24
- ROE-43.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-83.9% as of 2026-08-24
- Beta1.33 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How GLUE compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MONTE ROSA THERAPEUTICS INC looks technically
MONTE ROSA THERAPEUTICS INC (GLUE) is trading 22.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 216 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 30, in oversold territory (below 30). It just made a new 20-day low, its first since 2025-11-21, breaking below its recent trading range. It is 44.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 22.2% below its 200-day average, the long-term trend line — a long-term downtrend | -22.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.98 | $19.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $18.38 | $18.38 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 20.925. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 216 trading days ago — a "golden cross", a bullish long-term signal | 216 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control | 36.5 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 30, in oversold territory (below 30) | 29.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($14.17 to $16.86) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 4.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.77 | $25.77 |
|---|---|---|
| From the 52-week high | it is 44.5% below its 52-week high (its highest price of the past year) | -44.5% |
| Above the 52-week low | it is 232.6% above its 52-week low (its lowest price of the past year) | +232.6% |
| Below the 52-week high | it is 44.5% below its highest point of the past year | 44.5% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2025-11-21, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2025-11-21, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $45.56 (set on 2021-09-07) | $45.56 |
| Given back of the 52-week move | over the past year its closes ranged ($4.35 to $25.31), and it has given back around half of its rise from last year’s low — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.69 to $12.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 52.5% |
| From the all-time high | it is 68.6% below its all-time high | -68.6% |
| Nearest price level | it is trading 2.3% below a resistance level at $14.63 — a price it turned at twice since 2025-11-14, most recently on 2025-12-18. Since 2024-08-21 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.3% |
| All-time low | its lowest closing price on record is $2.44 (set on 2023-10-25) | $2.44 |
| Above the all-time low | it is 486.1% above its all-time low | +486.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 91% of the past ~6 months) | 91st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.17 between its high and its low — about 8.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.17 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.51 and $22.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.51 – $16.91 – $22.30 |
| Typical daily range (% of price) | its price moves about 8.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.2% |
| Stretch from the 200-day average | it is trading 3.5 daily ranges below its 200-day average price (22.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.71× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 31.8% below the previous close 15 sessions ago and has not traded back through the level it left behind at 22.68 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -31.8% |
| Gap filled | a 3.7% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -9.32% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 41.8 percentage points (the stock lost 39.5% while the market gained 2.3%) | -41.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.4 percentage points (the stock lost 24.3% while the market gained 3.1%) | -27.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 35.7 percentage points (the stock lost 24.7% while the market gained 11.1%) | -35.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 197.3 percentage points (the stock gained 217.8% while the market gained 20.5%) | +197.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 31% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 8.0% of the share price. | -30.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $19.97 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -28.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $15.44 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -7.4% |
Price levels it has turned at before
GLUE last closed at $14.30 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.63 | Resistance | 2.3% above the last close | turned there twice · 2025-11-14 to 2025-12-18 |
| $11.49 | Support | 19.7% below the last close | turned there twice · 2025-10-16 to 2025-11-04 |
| $10.69 | Support | 25.2% below the last close | turned there twice · 2024-12-02 to 2024-12-10 |
| $20.39 | Resistance | 42.5% above the last close | turned there twice · 2026-02-24 to 2026-05-29 |
| $7.43 | Support | 48.0% below the last close | turned there three times · 2024-11-19 to 2025-09-16 |
| $25.24 | Resistance | 76.5% above the last close | turned there three times · 2026-01-22 to 2026-07-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $20.93.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $17.30 and $20.02 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$28.50 range $25.00 – $37.00; median $27.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GLUE
- Consensus EPS estimate-$0.3469 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on strategic collaborations (Novartis and Roche partnerships) for revenue and product development success; significant revenue decline (-73% YoY in 2026) indicates substantial reliance on milestone payments that may be unpredictable.","Clinical development risk: multiple programs still in preclinical or early-stage clinical phases with uncertain timelines for IND applications, regulatory approval, and commercialization success.","Substantial operating losses and negative margins (-302.69% net margin) with high R&D spending; company will require continued funding to complete development and commercialization of product candidates."]
What changed in the latest 10-Q
AI-assisted comparison of GLUE's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 30 (2025-11-06 filing) to 28 (2026-05-07 filing)
- Page number for 'Controls and Procedures' changed from 30 (2025-11-06 filing) to 28 (2026-05-07 filing)
- Page number for 'PART II. OTHER INFORMATION' changed from 31 (2025-11-06 filing) to 29 (2026-05-07 filing)
- Page number for 'Item 1. Legal Proceedings' changed from 31 (2025-11-06 filing) to 29 (2026-05-07 filing)
- Notes:
- Only table of contents entries are provided in both source texts; substantive MD&A content is not included in the comparison
- Page number changes may reflect document length variations between periods but do not indicate content additions or removals
Risk Factors
- Added:
- Item 1A Risk Factors moved from page 31 to page 29 in newer filing
- Newer filing includes 'Collaboration receivable' line item ($0 as of March 31, 2026 vs $7,000 as of December 31, 2025) in balance sheet
- Newer filing shows 'Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance cost of $21,187' with 13,000,000 shares issued in Q1 2026
- Newer filing shows 'Exercise of pre-funded warrants' with 5,016,628 shares exercised in Q1 2026
- Newer filing includes 'Restricted common stock vesting' with 186,515 shares in Q1 2026
- Removed:
- Older filing included 'Collaboration receivable' line in balance sheet; removed from newer filing's current assets structure
- Older filing included comparison periods for three months and nine months ended September 30, 2025 and 2024; newer filing only shows three months ended March 31, 2026 and 2025
- Older filing included stockholders' equity statement showing balances through September 30, 2025 with interim periods (March 31, June 30); newer filing only shows January 1, 2026 through March 31, 2026
- Reworded:
- Balance sheet date changed from 'September 30, 2025 and December 31, 2024' in older filing to 'March 31, 2026 and December 31, 2025' in newer filing
- Operating statement period changed from 'Three months ended September 30' and 'Nine months ended September 30' in older filing to 'Three months ended March 31' in newer filing
- Consolidated statements comparison changed from 2025 vs 2024 periods to 2026 vs 2025 periods between filings
- Notes:
- The two filings represent different quarterly reporting periods (Q3 2025 ending September 30 in older filing vs Q1 2026 ending March 31 in newer filing), making period-to-period comparisons limited
- Older filing included historical nine-month data; newer filing only includes quarterly data
- Different number of stockholders' equity statement periods presented (older had multiple interim periods within the 2025 and 2024 comparison; newer shows only Q1 2026 periods)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 17 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 17 sells ($2M) — 5 selling insiders
- Last 180 days0 buys · 21 sells ($3M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-16. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GLUE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GLUE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,713,186
- Reported value $176,231,908
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GLUE had 16,458,543 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GLUE had 19.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.59 days to cover at the same settlement.
- Reported short interest (shares) 16,458,543
- Short interest (% of shares outstanding) 19.3%
- Prior settlement (shares) 17,195,471
- Reported change -4.29%
- Days to cover (reported) 10.59
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kymera Therapeutics (KYMR)
- Cerebras Systems
- Nurix Therapeutics (NRIX)
- Arvinas (ARVN)
- C4 Therapeutics (CCCC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GLUE vs…
MONTE ROSA THERAPEUTICS INC is found in…
Frequently asked questions
What does MONTE ROSA THERAPEUTICS INC (GLUE) do?
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing molecular glue degraders (MGDs), a class of small-molecule therapeutics designed to degrade disease-causing proteins. The company leverages its proprietary QuEEN discovery engine and proteomics capabilities to identify and target proteins previously considered undruggable or inadequately addressed by conventional approaches.
What sector is MONTE ROSA THERAPEUTICS INC (GLUE) in?
MONTE ROSA THERAPEUTICS INC (GLUE) is classified in the Health Care sector. Its industry is Protein degradation therapeutics / targeted protein degradation. It trades on NASDAQ.
Who are MONTE ROSA THERAPEUTICS INC's (GLUE) competitors?
Notable peers of MONTE ROSA THERAPEUTICS INC (GLUE) include Kymera Therapeutics, Cerebras Systems, Nurix Therapeutics, Arvinas and C4 Therapeutics. This peer set is informational only — not financial advice.
Is MONTE ROSA THERAPEUTICS INC (GLUE) overbought or oversold right now?
MONTE ROSA THERAPEUTICS INC (GLUE) is currently in oversold territory (its 14-day RSI is 30, below 30) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GLUE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.